Research programme: PYM 6001 series - IXICO

Drug Profile

Research programme: PYM 6001 series - IXICO

Alternative Names: P 61; P61 Programme; PYM 60001

Latest Information Update: 25 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Phytopharm
  • Developer IXICO; Phytopharm
  • Class
  • Mechanism of Action TRPV1 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Asthma; Chronic obstructive pulmonary disease; Inflammation
  • Discontinued Irritable bowel syndrome

Most Recent Events

  • 18 Feb 2011 Preclinical development is ongoing in the United Kingdom
  • 26 May 2010 The programme is still in active development for Asthma and Chronic obstructive pulmonary disease in the United Kingdom
  • 30 Jul 2007 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top